ACTR-13. EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFICATION RATES OBSERVED IN SCREENING PATIENTS FOR RANDOMIZED CLINICAL TRIALS IN GLIOBLASTOMA

by van den Bent, Martin, Roberts-Rapp, Lisa A, Ansell, Peter J, Lee, James, Looman, Jim, Bain, Earle, Ocampo, Christopher, Holen, Kyle D, Gomez, Erica J, Lassman, Andrew B
Published in Neuro Oncol (2017)

ACTR-68. CONCORDANCE OF EGFR AND MGMT ANALYSES BETWEEN LOCAL AND CENTRAL LABORATORIES: IMPLICATIONS FOR CLINICAL TRIAL DESIGN AND PRECISION MEDICINE FOR DEPATUXIZUMAB-MAFODOTIN (AB...

by Lassman, Andrew, Dimino, Cara, Mansukhani, Mahesh, Murty, Vundavalli, Ansell, Peter J, Bain, Earle, Holen, Kyle D, Roberts-Rapp, Lisa A, Lee, James, Curran, Walter, Mehta, Minesh P, Canoll, Peter
Published in Neuro Oncol (2017)

Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma

by Gan, Hui K, Reardon, David A, Lassman, Andrew B, Merrell, Ryan, van den Bent, Martin, Butowski, Nicholas, Lwin, Zarnie, Wheeler, Helen, Fichtel, Lisa, Scott, Andrew M, Gomez, Erica J, Fischer, JuDee, Mandich, Helen, Xiong, Hao, Lee, Ho-Jin, Munasinghe, Wijith P, Roberts-Rapp, Lisa A, Ansell, Peter J, Holen, Kyle D, Kumthekar, Priya
Published in Neuro Oncol (2018)

Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor

by Goss, Glenwood D., Vokes, Everett E., Gordon, Michael S., Gandhi, Leena, Papadopoulos, Kyriakos P., Rasco, Drew W., Fischer, JuDee S., Chu, Katharine L., Ames, William W., Mittapalli, Rajendar K., Lee, Ho‐Jin, Zeng, Jiewei, Roberts‐Rapp, Lisa A., Loberg, Lise I., Ansell, Peter J., Reilly, Edward B., Ocampo, Christopher J., Holen, Kyle D., Tolcher, Anthony W.
Published in Cancer (2018)